For Healthcare Professionals

Our trial will attempt to answer an important question for the primary prevention of cardiovascular disease.

Does targeting excess body weight with semaglutide in patients with resistant hypertension improve blood pressure control versus standard care?

The trial aims to recruit adult patients with obesity and resistant hypertension. First a pilot rial will determine how best to perform this work in the Irish healthcare setting

We hope you are interested in this trial and it is a valuable opportunity for your practice and its patients to be involved in ground-breaking research. This will be the first regulated drug trial performed by the HRB Primary Care Clinical Trials Research Network Ireland.

Your practice will be supported throughout by the trial team, led by the HRB PC-CTNI and Wellcome-HRB Clinical Research Facility at St James’s Hospital and Trinity College Dublin.

As well as practical support from the trial team, the trial includes practice supports for recruitment, measurements, rooms and GP time

Your role and that of your site will be to identify patients eligible for the study, with obesity (BMI > 30 kg/m2) and resistant hypertension (those on 3 antihypertensive medications and a mean home systolic BP ≥ 130 mmHg). BP can be based on a 24 hour ambulatory measurement or clinic readings initially.

With the trial team, you will invite the identified patient’s to attend for an initial (screening) visit. 

Patients will attend weekly dosing visits which will take less than 1 hour. We would also ask that a room is available for trial visits with patients. 

The trial team will inform the patients about the trial, consent patients for their participation, assess the patients according to the trial eligibility criteria, monitor safety events and perform follow-up assessments, with your input.

The trial is a regulated drug trial. For the practice, this involves trial related tasks such as reporting of any safety concerns, careful filing of trial documentation, prescribing of the trial drug and meeting with the Chief Investigators as required.

If you are interesting in contributing to this trial, we would be delighted to hear from you. Please contact us at [support-trial@tcd.ie] or call [trial phone number].